Research-only: Recovery / Joints (BPC-157 + TB4)

B84· Mostly solid

Public • 06 Feb 2026

Groups the two most commonly paired research peptides discussed in injury-repair circles; evidence is largely preclinical & not athlete-RCT grade.

← Back Try alternative layout

Buy stack

Research-only: Recovery / Joints (BPC-157 + TB4)

recovery joints research-only

BPC-157

PLACEHOLDER

MODERATE

1mg

TB500 (TB4 / Thymosin Beta-4)

PLACEHOLDER

MODERATE

1mg

No interactions detected

Each dose includes evidence rationale · doses personalized to your weight

Stack note

Private note on this stack

Track how this stack felt, what you want to change next cycle, or anything you want to save privately in your member zone.

AI risk assessment

Context: No wearable data

PROAI risk assessment is available with Pro.

See plans

Stack pre-check

No personal data connected — connect wearables or upload bloodwork for a personalised check

Clean

Supplements

Training load

Unknown

No flags

No duplication, stimulant, interaction, or recovery concerns detected.

Pre-check is rule-based, not medical advice. Consult a healthcare professional for personalised guidance.

Interaction Analysis

Pharmacokinetic + pair-level checks

Timing optimizations

BPC-157

Take ~1h before the intended effect window

Reaches peak plasma concentration in ~1h. Half-life ~4h.

TB500 (TB4 / Thymosin Beta-4)

Take ~1h before the intended effect window

Reaches peak plasma concentration in ~1h. Half-life ~4h.

Interaction analysis is based on peer-reviewed pharmacology. PMID links go to PubMed. Not medical advice.

Supplements

2 items

BPC-157Low

PLACEHOLDER • Lyophilized •

Preclinical tissue-repair signals; limited human evidence.

Buy ingredient →

1mg

Safety / pharmacokinetics

Low

Population: Healthy volunteers

Study type: Registered phase 1 trial (results not posted)

Dose context: — • Duration: See registry

A phase 1 safety/PK study in healthy volunteers was registered; results were not posted & the submission was canceled per later reviews, limiting interpretability.

Citation: ClinicalTrials.gov NCT02637284 — PCO-02 Safety and Pharmacokinetics Trial•https://clinicaltrials.gov/study/NCT02637284

Soft tissue healing signals (preclinical)

Low

Population: Animal models (multiple tissues)

Study type: Review (preclinical-focused)

Dose context: —

Multiple preclinical models report improvements in healing-related endpoints; translation to humans remains unproven.

Citation: Cushman et al., Local and Systemic Peptide Therapies for Soft Tissue Healing (2024)•https://pmc.ncbi.nlm.nih.gov/articles/PMC11426299/

Musculoskeletal healing (preclinical)

Low

Population: Animal injury models (multiple tissues)

Study type: Narrative review of preclinical evidence

Dose context: —

Across animal models, BPC-157 is frequently reported to improve healing-related outcomes (tendon/ligament/muscle/bone & GI injury models), but translation to humans remains unproven.

Citation: Vasireddi et al., (2025) — Emerging Use of BPC-157 in Orthopaedic Sports Medicine (review)•https://pmc.ncbi.nlm.nih.gov/articles/PMC12313605/

TB500 (TB4 / Thymosin Beta-4)Low

PLACEHOLDER • Lyophilized •

Wound-healing biology (mostly preclinical); not validated as an athlete recovery protocol.

Buy ingredient →

1mg

Wound healing (clinical development)

Low

Population: Patients with venous stasis ulcers

Study type: Registered phase 2 trial (TB4 gel)

Dose context: — • Duration: Up to 84 days (per registry)

TB4 gel has been studied in venous stasis ulcer indications; registry evidence supports clinical testing, though effect sizes depend on the specific trial & endpoint reporting.

Citation: ClinicalTrials.gov NCT00832091 — Thymosin Beta 4 in Venous Stasis Ulcers•https://clinicaltrials.gov/study/NCT00832091

Wound healing

Low

Population: Rat full-thickness wound model

Study type: Preclinical animal study

Dose context: —

TB4 accelerated wound healing endpoints in a rat model compared with controls.

Citation: Malinda et al., J Invest Dermatol (1999)•DOI: 10.1046/j.1523-1747.1999.00708.x•https://pubmed.ncbi.nlm.nih.gov/10469335/

Wound healing (reviewed clinical context)

Low

Population: Stasis and pressure ulcer clinical programs

Study type: Review article

Dose context: —

A review summarizes phase 2 wound-healing programs reporting faster healing in those that did heal; note that these are not sports injury RCTs.

Citation: Treadwell et al., Ann N Y Acad Sci (2012) — The regenerative peptide thymosin β4 accelerates the rate of dermal healing•https://pubmed.ncbi.nlm.nih.gov/23050815/